It was a medical enigma: Why do many black patients respond differently to a class of heart drugs called beta blockers? Researchers now say a genetic variant allows 40 percent of black patients to produce their own version of the drugs. Dr. Stephen Liggett tells The Takeaway about his study and the potential impacts on health care.
Guest: Dr. Stephen Liggett, director of Cardiopulmonary Genomics at University of Maryland Medical Center.